Comparative Efficacy of Novel Combination Strategies for Unresectable Hepatocellular Carcinoma (HCC): A Network Metanalysis of Phase III Trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative Efficacy of Novel Combination Strategies for Unresectable Hepatocellular Carcinoma (HCC): A Network Metanalysis of Phase III Trials

Published:2022 Issue: Volume: Page:
ISSN:1556-5068
Container-title:SSRN Electronic Journal
language:en
Short-container-title:SSRN Journal

Author:

Fulgenzi Claudia Angela Maria,D’Alessio Antonio,Airoldi Chiara,Scotti Lorenza,Demirtas Coskun O.,Gennari Alessandra,Cortellini Alessio,Pinato David J.

Publisher

Elsevier BV

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference36 articles.

1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma;R S Finn;N Engl J Med,2020

2. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study;Z Ren;Lancet Oncol,2021

3. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA;G K Abou-Alfa;Journal of Clinical Oncology,2022

4. Cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma: Results from the randomized phase III COSMIC-312 trial;R K Kelley;Annals of Oncology,2022

5. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update;M Reig;J Hepatol,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP